You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和铂医药-B(02142.HK):两产品已启动商业化前期工作
阿思达克 12-10 11:04
和铂医药-B(02142.HK)今日(10日)在联交所主板上市,主席及首席执行官王劲松表示,公司产品线中已有一部分药品处开发中後期,包括用於治疗多种自身免疫性疾病的「巴托利单抗」,目前已取得四个临床研究批件。而另一治疗乾眼病药品「特那西普」亦已获内地批准进行三期注册临床。

他指,两产品已启动组建团队等的商业化前期工作,相信随着公司更多药品陆续进入商业化阶段,加上研开过程中的技术转让及授权,可带来更多的商业回报,令公司有更佳的财务平衡。

王劲松又称,公司着重差异化优势及全球创新,认为是次在港上市令公司获得更好的资源及发展。(ek/w)

~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account